In the USA, toxoplasmosis is the second leading cause of foodborne illness–related death and hospitalization, with >300 deaths and 4000 hospitalizations each year [2]; 4800 people develop visual loss yearly secondary to the parasite.
Healio.com reports that pregnant women with APL antibodies and who took Plaquenil (HCQ or hydroxychloroquine) had better pregnancy outcomes than those who did not.
Patients in the U.S. with myositis who are positive for the anti-MDA5 autoantibody are at high risk for developing interstitial lung disease (ILD), a retrospective study found.
The FDA has denied Pfizer's application seeking an indication for Xeljanz in patients with moderate to severe chronic plaque psoriasis.
The CDC has reported in the NEJM that dietary supplements may be associated with higher than expected rates of adverse events requiring medical evaluation in the emergency department (ED).
The Journal of Clinical Investigation reports a potential decline in the number of medical researchers in the future.
Hydroxychloroquine (HCQ or Plaquenil) retinopathy is rare, but still a major concern among patients and prescribers.
This month's DSB addresses labeling changes as well as safety reports from literature, including steps to prevent major birth defects, timing and intervals between PCV13 and PPSV23 vaccines, PPIs and subacute cutaneous lupus, and FDA warnings on tramadol in children.
Nearly 2 weeks have passed since the painful launch of ICD-10 in US medical practices.
A new JAMA study shows new onset back pain treated with physical therapy yields modest short-term (3 months) improvement.
From 2003 to 2013, the percentage of nonmedical use of prescription opioids decreased among adults in the U.S., while the prevalence of prescription opioid use disorders, frequency of use, and related deaths increased, according to a study in the October 13 issue of JAMA.
Primary prevention of osteoarthritis is an ideal goal for which there has been little success in clinical trials.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
